



Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

Amgen Investor Relations
Mailstop 28-1-C

Phone: 805-447-1060

Fax: 805-499-0792

investor.relations@amgen.com

Stock Performance

AMGN (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$55.38
Change (%)	▼ 0.68 (1.21%)
Volume	9,325,176
52 Week Low	\$44.96
Market Cap	\$56,052,202,440
Rolling EPS	4.50
PE Ratio	12.3
Shares Outstanding	1,012,138,000

Data as of 11/20/09 4:00 p.m. ET



Recent Headlines

11/16/09

Amgen to Present at Lazard Capital Healthcare Conference

11/12/09

Amgen to Present at 18th Annual Credit Suisse Healthcare Conference

11/05/09

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer

11/04/09

Call for Applications: The Amgen Award for Science Teaching Excellence

10/30/09


Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: 1.9




EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Dec 09	1.21	1.25	1.25
QTR	Mar 10	1.20	1.19	1.17
QTR	Jun 10	1.27	1.28	1.28
QTR	Sep 10	1.30	1.32	1.33
FY	Dec 09	5.03	4.99	4.88
FY	Dec 10	5.14	5.11	5.10

SEC Filings

Filing Date	Form
11/18/09	4
11/17/09	4
11/16/09	CT ORDER
11/06/09	4

Financial Reports

 Q3 2009 Financial Results

Presentations

11/17/09  Lazard Capital Healthcare Conference Presentation

Management Team

David Beier
SVP, Global Government and Corporate Affairs

Fabrizio Bonanni, Dr. Chem.
EVP, Operations

Robert Bradway
EVP and CFO

Tom Flanagan
SVP and CIO

Brian McNamee
SVP, Human Resources

George Morrow
EVP, Global Commercial Operations

Roger M. Perlmutter, M.D., Ph.D
EVP, Research and Development

Anna Richo
SVP and Chief Compliance Officer

David Scott
SVP, General Counsel and Secretary

Kevin Sharer
Chairman of the Board, CEO and President

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed